Pre-order Enquiry
Request Free Sample
Global and Japan Oncolytic Virus Cancer Immunotherapy Market Size, Status and Forecast 2021-2027
SKU ID : QYR-19273333 | Publishing Date : 05-Oct-2021 | No. of pages : 107
Detailed TOC of Global and Japan Oncolytic Virus Cancer Immunotherapy Market Size, Status and Forecast 2021-2027
1 Report Overview1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Monoclonal Antibodies
1.2.3 Checkpoint Inhibitors
1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines
1.3 Market by Application
1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Head and neck Cancer
1.3.8 Ovarian Cancer
1.3.9 Pancreatic Cancer
1.3.10 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2016-2027)
2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Regions
2.2.1 Oncolytic Virus Cancer Immunotherapy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Share by Regions (2016-2021)
2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Regions (2022-2027)
2.3 Oncolytic Virus Cancer Immunotherapy Industry Dynamic
2.3.1 Oncolytic Virus Cancer Immunotherapy Market Trends
2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers
2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges
2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue
3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2016-2021)
3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2016-2021)
3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue
3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio
3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2020
3.5 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served
3.6 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
3.7 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type
4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2016-2021)
4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2022-2027)
5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application
5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2016-2021)
5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2016-2027)
6.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type
6.2.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021)
6.2.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027)
6.2.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2027)
6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application
6.3.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021)
6.3.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027)
6.3.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2027)
6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country
6.4.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021)
6.4.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2016-2027)
7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type
7.2.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021)
7.2.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027)
7.2.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2027)
7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application
7.3.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021)
7.3.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027)
7.3.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2027)
7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country
7.4.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021)
7.4.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size (2016-2027)
8.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type
8.2.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2027)
8.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application
8.3.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2027)
8.4 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.4.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2016-2027)
9.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type
9.2.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021)
9.2.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027)
9.2.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2027)
9.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application
9.3.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021)
9.3.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027)
9.3.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2027)
9.4 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country
9.4.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021)
9.4.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size (2016-2027)
10.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type
10.2.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2027)
10.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application
10.3.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2027)
10.4 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country
10.4.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction
11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction
11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 F Hoffman-La Roche
11.3.1 F Hoffman-La Roche Company Details
11.3.2 F Hoffman-La Roche Business Overview
11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction
11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.3.5 F Hoffman-La Roche Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Details
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction
11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.5.5 Novartis AG Recent Development
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Details
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction
11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.6.5 Merck & Co., Inc. Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction
11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.7.5 Pfizer Recent Development
11.8 Biovex
11.8.1 Biovex Company Details
11.8.2 Biovex Business Overview
11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction
11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.8.5 Biovex Recent Development
11.9 Cell Genesys
11.9.1 Cell Genesys Company Details
11.9.2 Cell Genesys Business Overview
11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction
11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.9.5 Cell Genesys Recent Development
11.10 Crusade Laboratories
11.10.1 Crusade Laboratories Company Details
11.10.2 Crusade Laboratories Business Overview
11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction
11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.10.5 Crusade Laboratories Recent Development
11.11 Genelux Corporation
11.11.1 Genelux Corporation Company Details
11.11.2 Genelux Corporation Business Overview
11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction
11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.11.5 Genelux Corporation Recent Development
11.12 Lokon Pharma
11.12.1 Lokon Pharma Company Details
11.12.2 Lokon Pharma Business Overview
11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction
11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.12.5 Lokon Pharma Recent Development
11.13 MultiVir
11.13.1 MultiVir Company Details
11.13.2 MultiVir Business Overview
11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction
11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
11.13.5 MultiVir Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Figures, Tables and Charts Available in Global and Japan Oncolytic Virus Cancer Immunotherapy Market Size, Status and Forecast 2021-2027
List of TablesTable 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Checkpoint Inhibitors
Table 4. Key Players of Oncoloytic Viral Therapies and Cancer Vaccines
Table 5. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Oncolytic Virus Cancer Immunotherapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Oncolytic Virus Cancer Immunotherapy Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Oncolytic Virus Cancer Immunotherapy Market Share by Regions (2016-2021)
Table 9. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Oncolytic Virus Cancer Immunotherapy Market Share by Regions (2022-2027)
Table 11. Oncolytic Virus Cancer Immunotherapy Market Trends
Table 12. Oncolytic Virus Cancer Immunotherapy Market Drivers
Table 13. Oncolytic Virus Cancer Immunotherapy Market Challenges
Table 14. Oncolytic Virus Cancer Immunotherapy Market Restraints
Table 15. Global Oncolytic Virus Cancer Immunotherapy Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players (2016-2021)
Table 17. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2020)
Table 18. Ranking of Global Top Oncolytic Virus Cancer Immunotherapy Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
Table 22. Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2016-2021)
Table 26. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Oncolytic Virus Cancer Immunotherapy Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2016-2021)
Table 30. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 62. AstraZeneca Company Details
Table 63. AstraZeneca Business Overview
Table 64. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product
Table 65. AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 66. AstraZeneca Recent Development
Table 67. Amgen Company Details
Table 68. Amgen Business Overview
Table 69. Amgen Oncolytic Virus Cancer Immunotherapy Product
Table 70. Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 71. Amgen Recent Development
Table 72. F Hoffman-La Roche Company Details
Table 73. F Hoffman-La Roche Business Overview
Table 74. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product
Table 75. F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 76. F Hoffman-La Roche Recent Development
Table 77. Bristol-Myers Squibb Company Details
Table 78. Bristol-Myers Squibb Business Overview
Table 79. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product
Table 80. Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 81. Bristol-Myers Squibb Recent Development
Table 82. Novartis AG Company Details
Table 83. Novartis AG Business Overview
Table 84. Novartis AG Oncolytic Virus Cancer Immunotherapy Product
Table 85. Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 86. Novartis AG Recent Development
Table 87. Merck & Co., Inc. Company Details
Table 88. Merck & Co., Inc. Business Overview
Table 89. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product
Table 90. Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 91. Merck & Co., Inc. Recent Development
Table 92. Pfizer Company Details
Table 93. Pfizer Business Overview
Table 94. Pfizer Oncolytic Virus Cancer Immunotherapy Product
Table 95. Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 96. Pfizer Recent Development
Table 97. Biovex Company Details
Table 98. Biovex Business Overview
Table 99. Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 100. Biovex Recent Development
Table 101. Cell Genesys Company Details
Table 102. Cell Genesys Business Overview
Table 103. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product
Table 104. Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 105. Cell Genesys Recent Development
Table 106. Crusade Laboratories Company Details
Table 107. Crusade Laboratories Business Overview
Table 108. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product
Table 109. Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 110. Crusade Laboratories Recent Development
Table 111. Genelux Corporation Company Details
Table 112. Genelux Corporation Business Overview
Table 113. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product
Table 114. Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 115. Genelux Corporation Recent Development
Table 116. Lokon Pharma Company Details
Table 117. Lokon Pharma Business Overview
Table 118. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product
Table 119. Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 120. Lokon Pharma Recent Development
Table 121. MultiVir Company Details
Table 122. MultiVir Business Overview
Table 123. MultiVir Oncolytic Virus Cancer Immunotherapy Product
Table 124. MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million)
Table 125. MultiVir Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type: 2020 VS 2027
Figure 2. Monoclonal Antibodies Features
Figure 3. Checkpoint Inhibitors Features
Figure 4. Oncoloytic Viral Therapies and Cancer Vaccines Features
Figure 5. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2020 VS 2027
Figure 6. Lung Cancer Case Studies
Figure 7. Breast Cancer Case Studies
Figure 8. Colorectal Cancer Case Studies
Figure 9. Melanoma Case Studies
Figure 10. Prostate Cancer Case Studies
Figure 11. Head and neck Cancer Case Studies
Figure 12. Ovarian Cancer Case Studies
Figure 13. Pancreatic Cancer Case Studies
Figure 14. Others Case Studies
Figure 15. Oncolytic Virus Cancer Immunotherapy Report Years Considered
Figure 16. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 17. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 18. Global Oncolytic Virus Cancer Immunotherapy Market Share by Regions: 2020 VS 2027
Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market Share by Regions (2022-2027)
Figure 20. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players in 2020
Figure 21. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2020
Figure 22. The Top 10 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2020
Figure 23. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2016-2021)
Figure 24. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2022-2027)
Figure 25. North America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. North America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2016-2027)
Figure 27. North America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2016-2027)
Figure 28. North America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2016-2027)
Figure 29. United States Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Canada Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Type (2016-2027)
Figure 33. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Application (2016-2027)
Figure 34. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Country (2016-2027)
Figure 35. Germany Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. France Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. U.K. Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Italy Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Russia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Nordic Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Type (2016-2027)
Figure 43. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Application (2016-2027)
Figure 44. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Region (2016-2027)
Figure 45. China Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Japan Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. South Korea Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. India Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Australia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2016-2027)
Figure 53. Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2016-2027)
Figure 54. Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2016-2027)
Figure 55. Mexico Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Brazil Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Type (2016-2027)
Figure 59. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Application (2016-2027)
Figure 60. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Country (2016-2027)
Figure 61. Turkey Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. UAE Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 64. AstraZeneca Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 65. Amgen Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 66. F Hoffman-La Roche Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 67. Bristol-Myers Squibb Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 68. Novartis AG Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 69. Merck & Co., Inc. Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 70. Pfizer Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 71. Biovex Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 72. Cell Genesys Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 73. Crusade Laboratories Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 74. Genelux Corporation Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 75. Lokon Pharma Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 76. MultiVir Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
Keyplayers in Global and Japan Oncolytic Virus Cancer Immunotherapy Market Size, Status and Forecast 2021-2027
AstraZenecaAmgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
Request Sample
Request Discount
